---
layout: post
title: "再生元制药和赛诺菲治疗嗜酸细胞性食管炎dupilumab获美国FDA优先审核"
date: 2022-04-04 15:28:59 +0800
categories: gelonghui
tags: 格隆汇新闻
---
<p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/105.SNY" data-code="SNY|105|7" data-code2="SNY|105|3|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.SNY&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 SNY_0" data-code="K SNY|105|7" data-code2="K SNY|105|3|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p style="display:none;height:1px;overflow:hidden;"><br /></p><!-- EM_StockImg_Start --><p style="text-align:center;"><a href="http://quote.eastmoney.com/unify/r/105.REGN" data-code="REGN|105|7" data-code2="REGN|105|1|" class="EmImageRemark" target="_blank"><img src="https://webquoteklinepic.eastmoney.com/GetPic.aspx?nid=105.REGN&imageType=k&token=28dfeb41d35cc81d84b4664d7c23c49f&at=1" border="0" alt="K图 REGN_0" data-code="K REGN|105|7" data-code2="K REGN|105|1|" style="border:#d1d1d1 1px solid;" width="578" height="276" /></a></p><!-- EM_StockImg_End --><p>格隆汇4月4日丨再生元制药(REGN.US)和赛诺菲宣布，美国FDA拟优先审核治疗成人和青少年嗜酸细胞性食管炎(EoE)的dupilumab(Dupixent)。Dupilumab是再生元制药(REGN.US)和赛诺菲(SNY.US)根据一项全球合作协议共同开发的。 <br /></p><p class="em_media">（文章来源：格隆汇）</p>

<http://finews.zning.xyz/html_News/NewsShare.html?infoCode=NW202204042332495722>

[返回格隆汇新闻](//finews.withounder.com/category/gelonghui.html)｜[返回首页](//finews.withounder.com/)